Retatrutide UK: Complete Evidence-Based Guide

The Revolutionary Triple-Agonist Peptide for Weight Loss | Clinical Trial Data, UK Availability & Safety Information

Home > Peptides > Retatrutide UK

What is Retatrutide? (Quick Answer)

Retatrutide is a triple-agonist peptide medication that activates GLP-1, GIP, and glucagon receptors for weight loss and metabolic health. Clinical trials show up to 24.2% weight loss over 48 weeks and 28.7% at 68 weeks—potentially superior to Wegovy and Mounjaro.

UK Availability: Not yet approved in the UK. Currently in Phase 3 clinical trials with expected completion in May 2026. Earliest UK availability: late 2026 or 2027 pending MHRA approval.

⚠️ Important Legal Notice for UK Residents

Retatrutide is NOT approved for human use in the UK. Any products claiming to be Retatrutide for personal use are illegal and potentially dangerous. The MHRA has issued warnings and conducted raids on facilities producing counterfeit weight loss medications. Only participate in authorized clinical trials under medical supervision.

What is Retatrutide?

Retatrutide (also known as LY3437943 or “Triple G”) is a synthetic peptide medication developed by Eli Lilly that functions as a triple hormone receptor agonist. Unlike existing weight loss medications, Retatrutide uniquely activates three distinct receptors simultaneously.

The Three Receptors Retatrutide Targets:

  1. GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows gastric emptying, and increases feelings of fullness. This helps reduce calorie intake by making you feel satisfied for longer periods.
  2. GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin secretion after meals, improves blood glucose control, and optimizes fat metabolism. This helps your body process and store fat more efficiently.
  3. Glucagon Receptor: Increases energy expenditure and promotes fat burning by stimulating the breakdown of stored fat into fatty acids that can be used for energy. This is what sets Retatrutide apart from other medications.

Why This Matters: By targeting three receptors instead of one (like Wegovy) or two (like Mounjaro), Retatrutide offers a more comprehensive approach to weight loss—reducing appetite, improving metabolism, AND increasing fat burning simultaneously.

How Retatrutide Works

Retatrutide’s molecular structure adopts a single continuous helical formation that allows it to bind uniquely to all three receptor types. The N-terminal segment engages with the receptor transmembrane domain, while C-terminal segment interacts with extracellular regions of the GLP-1 and GIP receptors.

Receptor Potency (EC50 values):

  • GIP receptor: 0.0643 nM (highest potency)
  • GLP-1 receptor: 0.775 nM
  • Glucagon receptor: 5.79 nM

The medication has a half-life of approximately 6 days, allowing for convenient once-weekly subcutaneous injections. It undergoes primarily hepatic metabolism without significant interaction with cytochrome P450 enzymes.

Clinical Trial Results: How Effective is Retatrutide?

Phase 2 Results (48 weeks): Up to 24.2% average weight loss with 12mg dose
Phase 3 TRIUMPH-4 Results (68 weeks): 28.7% average weight loss (71.2 lbs / 32.3 kg) with 12mg dose

Detailed Phase 2 Clinical Trial Results

In the pivotal Phase 2 study published in The New England Journal of Medicine, participants with obesity were treated with various doses of Retatrutide over 48 weeks:

  • 12mg dose: 24.2% average weight loss, with 26% of participants losing ≥30% of body weight
  • 8mg dose: Significant weight loss with improved tolerability
  • 4mg dose: 17% average weight loss
  • At 24 weeks: Up to 17.5% weight reduction observed

Phase 3 TRIUMPH-4 Trial Results

The first Phase 3 trial results (announced December 2024) demonstrated even more impressive outcomes for participants with obesity and knee osteoarthritis:

  • Average weight loss: 71.2 lbs (32.3 kg) or 28.7% of starting body weight at 68 weeks
  • Pain reduction: 75.8% reduction in knee pain (4.5 points on WOMAC scale)
  • Consistency: Results maintained across diverse participant demographics

What This Means: These results represent some of the highest weight loss percentages ever achieved with medication alone—approaching outcomes typically seen only with bariatric surgery, but without the surgical risks.

Metabolic Benefits Beyond Weight Loss

Clinical trials have demonstrated additional health improvements:

  • Significant improvements in HbA1c (blood sugar control)
  • Improved insulin sensitivity
  • Reduced liver fat (beneficial for NAFLD/fatty liver disease)
  • Better lipid profiles (cholesterol levels)
  • Reduced cardiovascular risk markers
  • Decreased visceral (dangerous belly) fat

How Does Retatrutide Compare to Wegovy and Mounjaro?

Medication Receptors Targeted Average Weight Loss UK Availability
Wegovy (Semaglutide) GLP-1 only 14.9-21% (depending on dose)
15% at 2.4mg
21% at 7.2mg		 ✅ Available now
(NHS & Private)
Mounjaro (Tirzepatide) GLP-1 + GIP 20-22.5%
(15mg dose at 72 weeks)		 ✅ Available now
(NHS & Private)
Retatrutide GLP-1 + GIP + Glucagon 24.2% (48 weeks)
28.7% (68 weeks)
(12mg dose)		 ❌ Not yet available
(Expected 2026-2027)

Key Differences Explained

Wegovy (Semaglutide): The first major breakthrough in GLP-1 medications for weight loss. Works primarily by reducing appetite and slowing digestion. Proven track record with extensive safety data. Good option for most people seeking significant weight loss.

Mounjaro (Tirzepatide): Added GIP receptor activation to GLP-1, creating a dual-agonist approach. Typically produces more weight loss than Wegovy and may be better for people with type 2 diabetes. Currently shows the best results among approved medications.

Retatrutide: The next generation—adds glucagon receptor activation for enhanced fat burning and energy expenditure. Early data suggests superior weight loss to both Wegovy and Mounjaro. However, it’s not yet approved and long-term safety data is still being collected.

Which is Best?

For now: Wegovy and Mounjaro are your proven options. Both are approved, available in the UK, and have established safety profiles. Mounjaro currently shows the highest weight loss among approved medications.

In the future: Retatrutide may become the new gold standard if Phase 3 trials confirm the impressive Phase 2 results and demonstrate acceptable long-term safety.

Is Retatrutide Available in the UK?

No. Retatrutide is NOT currently available in the UK for medical use. It has not been approved by the MHRA (Medicines and Healthcare products Regulatory Agency) or NICE (National Institute for Health and Care Excellence).

Current Status (January 2026)

  • Phase 3 clinical trials ongoing – Multiple TRIUMPH trials in progress
  • Expected trial completion: May 2026
  • FDA application: Likely submitted mid-to-late 2026
  • FDA review period: Typically 6-10 months
  • UK MHRA approval: Could follow US approval
  • Earliest UK availability: Late 2026 or more likely 2027

Beware of Illegal Sales

Warning: Some websites, TikTok sellers, and Telegram groups claim to sell Retatrutide as “research peptides” or “for laboratory use only.” These products are:

  • ❌ Not approved for human use in the UK
  • ❌ Unregulated and potentially dangerous
  • ❌ Illegal to market for human consumption
  • ❌ May contain unknown or harmful substances
  • ❌ Often counterfeit or contaminated

MHRA Action: In October 2025, the MHRA conducted the largest-ever seizure of illicit weight loss medicines in the UK, shutting down the first illegal Retatrutide production facility discovered in the country. They seized over 2,000 unlicensed pens and raw ingredients worth £250,000+.

How to Access Retatrutide Legally

The ONLY legal way to access Retatrutide in the UK is through authorized clinical trials.

To find legitimate clinical trials:

  1. Visit ClinicalTrials.gov and search “Retatrutide UK”
  2. Check if you meet eligibility criteria (usually BMI ≥27-30, aged 18-75)
  3. Contact trial center directly
  4. Undergo medical screening
  5. Receive medication, monitoring, and care at no cost

What About Research Use?

UK SARMs and other reputable suppliers may offer research-grade peptides including Retatrutide for legitimate scientific research purposes only. These products:

  • ✅ Are for laboratory research only
  • ✅ Include proper documentation and COAs
  • ✅ Are NOT for human consumption
  • ✅ Must be used by qualified researchers in appropriate facilities

Important: Self-administering research chemicals is dangerous and illegal.

What Are the Side Effects of Retatrutide?

Clinical trials show Retatrutide has a side effect profile similar to other GLP-1 medications, with gastrointestinal symptoms being most common.

Common Side Effects (Occurring in >10% of participants)

  • Nausea – Most common, especially when starting or increasing dose
  • Diarrhea – Usually temporary and manageable
  • Vomiting – Typically mild to moderate
  • Constipation – Can alternate with diarrhea

Less Common Side Effects (Occurring in <10% of participants)

  • Abdominal discomfort
  • Decreased appetite (this is also therapeutic)
  • Fatigue
  • Changes in skin sensation (tingling)
  • Headache

Managing Side Effects

Side effects are typically:

  • Mild to moderate in severity
  • Most common when starting treatment or increasing dose
  • Temporary—they usually improve over time
  • Manageable with dietary adjustments

Tips to minimize side effects: Eat smaller meals, avoid high-fat foods, stay hydrated, increase dose gradually, and take medication at bedtime initially.

Serious Side Effects (Rare)

As with all GLP-1 medications, potential serious side effects may include:

  • Pancreatitis (inflammation of the pancreas)
  • Gallbladder problems
  • Kidney problems
  • Severe hypoglycemia (when combined with certain diabetes medications)
  • Thyroid C-cell tumors (seen in rodent studies, theoretical risk in humans)

Important: In clinical trials, serious adverse events were rare and occurred at similar rates to placebo. However, long-term safety data (5+ years) is not yet available for Retatrutide.

Who Should NOT Use Retatrutide?

Based on clinical trial exclusion criteria and similar medications:

  • Personal or family history of medullary thyroid cancer
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Previous severe allergic reaction to GLP-1 medications
  • Pregnant or breastfeeding women
  • History of pancreatitis
  • Severe gastrointestinal disease
  • Under 18 years old

How is Retatrutide Administered?

Retatrutide is administered as a once-weekly subcutaneous (under the skin) injection, similar to Wegovy and Mounjaro.

Dosing Schedule (Based on Clinical Trials)

Participants typically follow this dose escalation schedule:

  1. Starting dose: 2mg once weekly (Weeks 1-4)
  2. First increase: 4mg once weekly (Weeks 5-8)
  3. Second increase: 6mg once weekly (Weeks 9-12)
  4. For 9mg group: Stay at 9mg (Week 13 onward)
  5. For 12mg group: Increase to 9mg, then 12mg (final dose)

Why Gradual Dosing? Starting at a low dose and increasing slowly helps minimize gastrointestinal side effects like nausea and allows your body to adjust to the medication.

Injection Technique

When approved, Retatrutide will likely use an injection pen similar to Mounjaro and Zepbound (also made by Eli Lilly). The injection is given:

  • In the abdomen (stomach area), thigh, or upper arm
  • Once weekly, on the same day each week
  • Can be taken with or without food
  • Rotate injection sites to prevent irritation

Storage

Research-grade lyophilized Retatrutide should be:

  • Stored in freezer before reconstitution
  • Refrigerated after reconstitution
  • Used within one week of reconstitution
  • Protected from light

(Note: Final approved product storage instructions may differ)

Comprehensive FAQ: Everything You Need to Know About Retatrutide

Can I buy Retatrutide legally in the UK right now?
No. Retatrutide is not approved for human use in the UK and cannot be legally purchased for personal consumption. Products marketed as Retatrutide for human use are illegal, unregulated, and potentially dangerous. The only legal way to access Retatrutide is through authorized clinical trials. The MHRA has actively raided facilities producing counterfeit weight loss medications.
How much will Retatrutide cost in the UK?
Pricing has not been announced, but it will likely be similar to or slightly higher than Mounjaro and Wegovy based on its advanced triple-agonist mechanism. Private prescription costs for similar medications in the UK currently range from £150-300+ per month. NHS availability will depend on NICE approval and cost-effectiveness assessments.
Will Retatrutide be available on the NHS?
Unknown at this time. If Retatrutide receives MHRA approval, NICE (National Institute for Health and Care Excellence) will need to evaluate its cost-effectiveness before approving NHS coverage. This typically takes additional months or years after initial approval. Wegovy took several years to become available on the NHS after initial approval.
Is Retatrutide better than Ozempic?
Clinical trial data suggests Retatrutide produces more weight loss than Ozempic (semaglutide 1mg). However, Ozempic is approved for type 2 diabetes, not weight loss. The fair comparison is Retatrutide vs Wegovy (semaglutide 2.4mg or 7.2mg for weight loss). Early data shows Retatrutide may produce 5-10% more weight loss, but head-to-head trials have not been conducted.
How long does it take to see results with Retatrutide?
Based on clinical trial data, most participants notice reduced appetite within the first few weeks. Weight loss becomes noticeable by 4-8 weeks. Average weight loss at different timepoints: 1 month: 2-5%, 3 months (12 weeks): 8-12%, 6 months (24 weeks): 15-17.5%, 12 months (48 weeks): 20-24.2%. Individual results vary based on starting weight, adherence to diet/exercise, and dosage.
Can I use Retatrutide if I’m already taking Wegovy or Mounjaro?
No. You should not combine GLP-1 medications or switch between them without medical supervision. If Retatrutide becomes available and you want to switch from Wegovy or Mounjaro, you’ll need to work with a healthcare provider to safely transition between medications.
Does Retatrutide help with diabetes as well as weight loss?
Yes. Retatrutide is being studied for both weight loss and type 2 diabetes management. Clinical trials (TRIUMPH-2) specifically evaluate its effectiveness in people with type 2 diabetes. Results show significant improvements in HbA1c (blood sugar control) alongside substantial weight loss. The triple-agonist mechanism may provide superior glucose control compared to single-agonist medications.
Will I regain weight after stopping Retatrutide?
Based on studies with similar medications (Wegovy, Mounjaro), most people regain weight after stopping treatment. These medications work by altering hormone signaling—when you stop taking them, those effects cease. Long-term weight maintenance typically requires continued medication use combined with lifestyle changes. This is why these are considered chronic treatments for obesity, similar to medications for high blood pressure or diabetes.
Does Retatrutide preserve muscle mass during weight loss?
Early data suggests Retatrutide may preserve lean body mass (muscle) better than earlier GLP-1 medications. This is potentially due to the glucagon receptor activation, which may promote fat oxidation preferentially over muscle breakdown. However, some muscle loss is inevitable with significant weight loss. Combining Retatrutide with resistance training and adequate protein intake can help maximize muscle preservation.
Can I drink alcohol while taking Retatrutide?
There are no specific contraindications for alcohol with Retatrutide based on current clinical trial data. However, alcohol can increase gastrointestinal side effects and contains empty calories that may impede weight loss goals. Additionally, if you have diabetes, alcohol can affect blood sugar levels. Moderate consumption is generally acceptable but discuss with your healthcare provider.
Is Retatrutide safe for long-term use?
Short to medium-term data (up to 68 weeks) from clinical trials shows acceptable safety with side effects primarily being gastrointestinal and generally mild to moderate. However, long-term safety data (3-5+ years) is not yet available. Ongoing Phase 3 trials and post-marketing surveillance will provide this information once the medication is approved and in widespread use.

Current Legal Alternatives Available in the UK

While waiting for Retatrutide approval, several proven weight loss medications are currently available in the UK:

1. Wegovy (Semaglutide)

  • Status: ✅ Approved and available
  • Weight Loss: 15-21% average (depending on dose)
  • Availability: NHS (with eligibility criteria) and private prescription
  • Best for: First-time GLP-1 users, proven track record

2. Mounjaro (Tirzepatide)

  • Status: ✅ Approved and available
  • Weight Loss: 20-22.5% average
  • Availability: NHS (limited) and private prescription
  • Best for: People with type 2 diabetes, those seeking maximum weight loss with current medications

3. Saxenda (Liraglutide)

  • Status: ✅ Approved and available
  • Weight Loss: 5-10% average
  • Availability: Private prescription only
  • Best for: Daily injection preference, lower cost option

Getting Started Today

If you’re interested in weight loss medication, you don’t have to wait for Retatrutide. Wegovy and Mounjaro are producing excellent results for thousands of UK residents right now. Consult with a healthcare provider to determine which option is right for you.

Future of Retatrutide: What’s Next?

Ongoing Clinical Trials

Eli Lilly is conducting multiple Phase 3 TRIUMPH trials evaluating Retatrutide for:

  • TRIUMPH-1: Obesity and overweight (general population)
  • TRIUMPH-2: Type 2 diabetes with obesity/overweight
  • TRIUMPH-3: Obstructive sleep apnea
  • TRIUMPH-4: Knee osteoarthritis (COMPLETED – results announced)
  • Additional trials: Cardiovascular outcomes, liver disease (MASH/NAFLD), chronic low back pain

Timeline to Market

May 2026: Expected completion of Phase 3 trials
Mid-Late 2026: Potential FDA application submission
Late 2026 or 2027: Possible FDA approval (if successful)
2027-2028: Potential UK MHRA approval and launch

Potential Game-Changing Applications

Beyond weight loss, Retatrutide shows promise for:

  • Metabolic-associated fatty liver disease (MAFLD/NASH): Early data shows significant liver fat reduction
  • Cardiovascular health: Improvements in blood pressure, lipids, and inflammatory markers
  • Joint health: TRIUMPH-4 showed 75.8% reduction in knee pain alongside weight loss
  • Sleep apnea: Being studied for moderate-to-severe obstructive sleep apnea
  • Longevity and healthy aging: Potential benefits for metabolic health and inflammation

Interested in Research-Grade Peptides?

UK SARMs offers high-purity research peptides for legitimate scientific research purposes only. All products include Certificates of Analysis (COA) and are manufactured to the highest standards.

View Research Peptides

Products are for research purposes only. Not for human consumption.

Important Disclaimers

Medical Advice: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any weight loss medication or supplement.

Research Products: Any research-grade peptides offered by UK SARMs are strictly for laboratory research purposes only. They are not intended for human consumption, and any use outside of authorized research settings is prohibited.

Regulatory Status: Retatrutide is not approved by the MHRA, FDA, EMA, or any other regulatory agency for human use. Information is based on clinical trial data and may change as studies progress.

Not a Substitute for Lifestyle: Weight loss medications work best when combined with a healthy diet and regular physical activity. They are not a replacement for lifestyle modifications.

Individual Results Vary: Clinical trial results represent averages. Individual weight loss and side effects may differ based on genetics, adherence, lifestyle factors, and other variables.

Summary: Key Takeaways About Retatrutide

  • Retatrutide is a revolutionary triple-agonist peptide that targets GLP-1, GIP, and glucagon receptors for comprehensive metabolic benefits
  • Clinical trials show impressive results – up to 24.2% weight loss at 48 weeks and 28.7% at 68 weeks, exceeding current medications
  • Not yet available in the UK – still in Phase 3 clinical trials with expected availability in 2026-2027 at the earliest
  • Illegal to buy for personal use – MHRA has warned against and raided facilities producing counterfeit Retatrutide
  • Similar side effect profile to other GLP-1 medications – mainly gastrointestinal symptoms that are typically mild and temporary
  • May be superior to Wegovy and Mounjaro – early data suggests enhanced weight loss and metabolic benefits, but head-to-head trials are needed
  • Multiple therapeutic applications – being studied for obesity, diabetes, fatty liver disease, sleep apnea, and joint pain
  • Current alternatives available – Wegovy and Mounjaro are providing excellent results for UK residents now

Stay Updated on Retatrutide Developments

The landscape of weight loss medications is evolving rapidly. To stay informed about Retatrutide’s progress toward UK approval:

  1. Monitor ClinicalTrials.gov for TRIUMPH trial updates and results
  2. Follow Eli Lilly’s investor relations for official announcements
  3. Check MHRA website for regulatory updates in the UK
  4. Consult reputable medical sources like The New England Journal of Medicine for peer-reviewed research
  5. Subscribe to UK SARMs newsletter for updates on research peptides and regulatory changes

Remember: Always verify information from multiple reputable sources and consult healthcare professionals before making decisions about weight loss medications.

References and Sources

This comprehensive guide is based on peer-reviewed clinical research and official regulatory sources:

  1. Jastreboff AM, et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine, 389(6), 514-526.
  2. Eli Lilly and Company. (2024). “Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” Press Release.
  3. Ma J, et al. (2024). “Comparison of effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.” Endocrine, 10.1007/s12020-024-03998-8.
  4. MHRA. (2025). “MHRA smashes major illicit weight loss medicine production facility in record seizure.” UK Government Press Release.
  5. ClinicalTrials.gov. “Retatrutide (LY3437943) Clinical Trials.” Available at: clinicaltrials.gov
  6. European Pharmaceutical Review. (2024). “Retatrutide—A Game Changer in Obesity Pharmacotherapy.” PMC, PMC12190491.
  7. GoodRx. (2025). “Retatrutide for Weight Loss: Availability, Dosage, and More.”

This page is regularly updated as new clinical trial data and regulatory information becomes available.